Insulet price target lowered to $200 from $213 at Barclays

Barclays analyst Matt Miksic lowered the firm’s price target on Insulet to $200 from $213 and keeps an Equal Weight rating on the shares post the Q1 report. Management delivered a solid beat, albeit against tempered expectations, driven by unexpected strength in Omnipod outside the U.S., the analyst tells investors in a research note. However, an expected step-up in tax drove the firm’s earnings estimates lower in 2024, 2025 and beyond.